Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Epstein-Barr virus predicts outcome in nasopharyngeal carcinoma

24.09.2008
Researchers in Hong Kong report that testing patient blood for DNA from Epstein-Barr virus (EBV) during treatment for nasopharyngeal carcinoma effectively predicts clinical outcome. A biomarker test like this, when perfected, could identify patients whose treatment could be intensified after a month or so of standard therapy as well as those who might benefit from lighter treatment.

The study, presented at the American Association for Cancer Research Molecular Diagnostics in Cancer Therapeutic Development meeting held here September 22-25, highlights the strong link between the virus and this cancer, which is common in Southern China and also develops in Chinese immigrants It further suggests that genetic levels of EBV should be assessed before and during treatment, not just after therapy, as it is now.

"We found that patients with undetectable EBV DNA mid-course through treatment had a greatly reduced risk of developing cancer recurrence two years after treatment, compared with patients with detectable EBV DNA," said the study's senior investigator, Anthony Chan, M.D., director of the Cancer Center at the Chinese University of Hong Kong.

Although EBV is associated with nasopharynx cancer, which develops in the upper area of the throat, a causal relationship hasn't been established, Chan says. Still, cancer cells contain EBV genetic material, which leaks into the bloodstream and can be detected using DNA tests. "That means a larger number of nasopharynx cancer cells in the body would give rise to a larger amount of EBV genetic material in the blood circulation, and so the EBV DNA level is a marker of the extent of cancer."

Researchers know that the amount of EBV DNA found after treatment is a recognized prognostic marker of survival because residual detectable EBV DNA "implies incomplete killing of cancer and thus a poor prognosis," Chan said. The question the researchers investigated is whether there is a way to identify patients with such a viral load before treatment is finished so that more aggressive therapy might be instituted.

"We need to know what to do for those patients with residual EBV. These patients usually do not have clinical evidence of cancer at that point and the residual cancer burden is at a microscopic level. Any extra treatment would be for undetectable cancer, and we need to prove that such treatment has an impact on improving survival," Chan said.

In this study, researchers tested 108 patients with advanced stage cancer for EBV DNA before the start of treatment, after a month of therapy, and then within three months after completion of treatment, and matched these levels to outcomes two-years later. They found that 94 percent of patients had detectable EBV DNA before therapy, but that it became undetectable in 54 percent of patients midway through treatment. The 42 percent of patients who had both low pretreatment and undetectable four-week viral levels constituted a "good risk group" because their recurrence rate was only nine percent.

Conversely, they found that levels detected after four weeks of treatment correlated with detectable post-treatment amounts, with an almost threefold greater risk of cancer recurrence and threefold higher risk of distant metastasis at two years.

"It is possible to test for EBV DNA levels at any time point, so based on further validation studies, we may be able to use biomarker levels at several time points to guide clinical therapy," Chan said.

Jeremy Moore | EurekAlert!
Further information:
http://www.aacr.org

More articles from Life Sciences:

nachricht Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs
16.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Cholera bacteria infect more effectively with a simple twist of shape
13.01.2017 | Princeton University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Multiregional brain on a chip

16.01.2017 | Power and Electrical Engineering

New technology enables 5-D imaging in live animals, humans

16.01.2017 | Information Technology

Researchers develop environmentally friendly soy air filter

16.01.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>